Rabbit antibodies show promise for rare bone marrow disease
NCT ID NCT00471848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of rabbit antithymocyte globulin (Thymoglobuline) and ciclosporin in 35 people with acquired aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this rabbit-based immune-suppressing treatment could improve blood counts and reduce the need for transfusions. Results were compared to historical data from patients who received a similar treatment made from horse antibodies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rabbit antithymocyte globulin (Thymoglobuline) with ciclosporin
What this could lead to
If successful, this could offer an alternative first-line immune-suppressing treatment for people with aplastic anemia, potentially improving blood cell counts and reducing transfusion needs.
What could go wrong
This is a small, early-phase study (35 participants) with no control group, so results are preliminary. The treatment involves strong immune suppression, which carries risks like infection and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
Henri Mondor Hospital
Créteil, France
-
Hopital St. Louis
Paris, 75475, France
-
King Faisal Specialist Hospital & Research Cnetre
Riyadh, Saudi Arabia
-
King's College Hospital
London, United Kingdom
-
Medical University Hannover
Hanover, Germany
-
Nottingham Universitry Hospital Trust
Nottingham, United Kingdom
-
Ospedale San Martino
Genova, 16132, Italy
-
Royal Bournemouth
Bournemouth, United Kingdom
-
St George's Hospital/ St George's University of London
London, Sw17 0RE, United Kingdom
-
University Hospital
Basel, 4031, Switzerland
-
University Hospital Eppendorf
Hamburg, Germany
-
University Hospital Essen
Essen, Germany
-
Universitätsklinikum - Institut für klinische Transfusionsmedizin
Ulm, 89081, Germany